NVAX FY 2013 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

FY 2013 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M-5.3% YoY

Gross Profit

$13M60.7% margin

Operating Income

-$52M-250.7% margin

Net Income

-$52M-248.5% margin

EPS (Diluted)

$-6.13

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$51M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$236M

Total Liabilities

$33M

Stockholders' Equity

$203M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$22M	-5.3%
Gross Profit	$13M	$7M	+71.9%
Operating Income	-$52M	-$30M	-76.8%
Net Income	-$52M	-$29M	-82.4%